The global ophthalmology drugs market size is calculated at US$ 43.22 billion in 2024, grew to US$ 45.52 billion in 2025, and is projected to reach around US$ 72.59 billion by 2034. The market is expanding at a CAGR of 5.33% between 2025 and 2034.
Rising Efforts from Key Market Players: The key market players are taking efforts to provide ophthalmology drugs. Various companies are collaborating with each other to develop high-quality drugs. Apart from this, a lot of investments are also being made in drug development.
For instance,
Finding and creating possible therapeutic candidates, manufacturing the medication, performing clinical trials, and identifying disease targets are some of the crucial steps in ophthalmology drug research and development. Along with making sure the medication satisfies certain ophthalmic needs like sterility and eye comfort, this procedure also involves optimising drug delivery techniques.
Top Companies: Allergan (now part of AbbVie), Novartis, Bausch + Lomb, and Alcon (a division of Novartis).
Preclinical research, clinical trials (Phases 1-3), and a New Drug Application (NDA) evaluation by regulatory agencies such as the FDA are all steps in the multi-stage process that goes into developing and approving medications for ophthalmology. For continuous safety monitoring, post-market surveillance (Phase 4) is also essential.
Top Companies: Ora, Inc., Lindus Health, ICON plc, PPD (Thermo Fisher Scientific), Syneos Health, and Labcorp Drug Development.
In order to maintain patient safety and regulatory compliance, ophthalmology medication packaging and serialisation require careful consideration of sterility, material selection, and serialisation parameters.
Top Companies: Alcon, Johnson & Johnson, Novartis, Bausch & Lomb, and Allergan (now part of AbbVie).
Education, help with administration, and addressing any adherence challenges are all part of patient care and services in ophthalmology, especially when it comes to medication administration. This include educating patients about medication combinations, making sure they know how to administer their eye drops properly, and giving assistance to people who have cognitive or physical impairments.
Top Companies: Allergan (now AbbVie), Bausch + Lomb, Novartis, Alcon, Johnson & Johnson Vision, Santen Pharmaceutical, and Cipla.
In June 2025, new treatments and research will be supported by an unprecedented $40 million donation to the CU Anschutz Department of Ophthalmology. "As the chair of the CU Department of Ophthalmology and the Sue Anschutz-Rodgers Endow Chair in Retinal Diseases, we have a fantastic opportunity to drive our research enterprise, which is essential to clinical care," stated Naresh Mandava, MD. With your contribution, we will be able to get technologies from the lab to the patient more quickly than previously.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
